First Time Loading...

Spero Therapeutics Inc
NASDAQ:SPRO

Watchlist Manager
Spero Therapeutics Inc Logo
Spero Therapeutics Inc
NASDAQ:SPRO
Watchlist
Price: 1.46 USD 2.1% Market Closed
Updated: Apr 29, 2024

Spero Therapeutics Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Spero Therapeutics Inc
Cash from Financing Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Spero Therapeutics Inc
NASDAQ:SPRO
Cash from Financing Activities
$221k
CAGR 3-Years
-88%
CAGR 5-Years
-68%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$17.2B
CAGR 3-Years
-14%
CAGR 5-Years
-4%
CAGR 10-Years
-17%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$5.1B
CAGR 3-Years
N/A
CAGR 5-Years
16%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
$21B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
23%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$562.2m
CAGR 3-Years
-4%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.8B
CAGR 3-Years
3%
CAGR 5-Years
-88%
CAGR 10-Years
N/A

See Also

What is Spero Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
221k USD

Based on the financial report for Dec 31, 2023, Spero Therapeutics Inc's Cash from Financing Activities amounts to 221k USD.

What is Spero Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-68%

The average annual Cash from Financing Activities growth rates for Spero Therapeutics Inc have been -88% over the past three years , -68% over the past five years .